Arch Therapeutics, Inc. is a biotechnology company based in Framingham, MA, specializing in the development of innovative wound care products. Their advanced approach aims to stop bleeding, control leaking, and manage wounds during surgical procedures, trauma, and interventional care. Arch Therapeutics utilizes a self-assembling barrier technology platform to create products that provide faster and safer care for patients. With regulatory authorization to market their AC5 Advanced Wound System and AC5 Topical Hemostat in the United States and Europe, Arch Therapeutics is committed to advancing the field of interventional wound care.
Driven by a team of experienced leaders, Arch Therapeutics is dedicated to meeting the challenges of the biotechnology industry and developing cutting-edge solutions for the wound care market. Their product pipeline includes investigational devices such as AC5-G, AC5-V, and AC5 Surgical Hemostat, with the goal of addressing the needs of healthcare professionals and improving patient outcomes. As a company at the forefront of innovation, Arch Therapeutics is focused on revolutionizing wound care through their proprietary technology and commitment to excellence.
Generated from the website